Jeffrey Adam Novack - Nov 18, 2024 Form 4 Insider Report for CareDx, Inc. (CDNA)

Signature
/s/ Jeffrey Adam Novack
Stock symbol
CDNA
Transactions as of
Nov 18, 2024
Transactions value $
-$149,829
Form type
4
Date filed
12/3/2024, 04:31 PM
Previous filing
Nov 8, 2024
Next filing
Dec 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CDNA Common Stock Sale -$79.2K -3.66K -3.07% $21.65 115K Nov 18, 2024 Direct F1, F2
transaction CDNA Common Stock Sale -$17.8K -807 -0.7% $22.00 114K Nov 18, 2024 Direct F1
transaction CDNA Common Stock Sale -$23.6K -1.07K -0.94% $22.00 113K Nov 18, 2024 Direct F1
transaction CDNA Common Stock Sale -$8.76K -365 -0.32% $24.00 113K Nov 25, 2024 Direct F1
transaction CDNA Common Stock Sale -$20.6K -858 -0.76% $24.00 112K Nov 25, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 19, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.34 to $21.94, inclusive. The Reporting Person undertakes to provide to CareDx, Inc., any security holder of CareDx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.